Drugmaker stock surges 156% in a single session after data on cancer vaccine

Shares of Sellas Life Sciences experienced a historic surge on Tuesday, jumping over 150% in a single trading session. This dramatic move was driven by positive data released regarding a cancer vaccine candidate, which sparked intense investor interest in the company's potential to treat the disease.
For investors, this event highlights the high-risk, high-reward nature of biotechnology stocks. A breakthrough in clinical trials can lead to explosive price movements, but such volatility is common in this sector. The stock's performance suggests that the market is pricing in significant future potential for the vaccine.
Moving forward, investors should monitor the company's official press releases and upcoming clinical trial updates. The stock's future direction will likely depend on the broader market's reaction to the new data and the company's ability to provide further details on its development plans.
Excerpt from CNBC-TV18
Published On Nov 18, 2026 | 10:33 IST Last Updated On Nov 18, 2026 | 10:33 IST The 156% surge seen in shares of Sellas Life Sciences was the biggest single-day gain since 2020. At the day's high, the stock was up 233% during Tuesday's trade. Shares of Sellas Life Sciences Group Inc. gained 156% on Tuesday, November 17…Read the original at CNBC-TV18
Key takeaways
- Category: Economy.
- AI reads the tone as positive (potentially bullish) for the stock.
- Flagged as a high-impact, market-moving story.
Why it matters
This is a high-impact development and could move the stock. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.











